Author

V. Chung

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:benchmark study· 1 Assay:bulk RNA-seq· 1 Assay:clinical cohort / trial· 1

Frequent Co-Authors

J. Guinney· 2 shared J. TangiD· 2 shared W. Wang· 2 shared A. Califano· 1 shared A. D. Sahu· 1 shared A. Fernandez-Torras· 1 shared A. Pessia· 1 shared A. S. Halkola· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Guinney

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A Community Challenge to Predict Clinical Outcomes After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

M. Mason, O. Lapuente-Santana, A. S. Halkola, W. Wang, R. Mall, X. Xiao, J. Kaufman, J. Fu, J. Pfeil, J. Banerjee, V. Chung, H. Chang, S. D. Chasalow, H. Y. Lin, R. Chai, , B. G. Vincent

The paper evaluates predictive models for immune checkpoint inhibitor outcomes in NSCLC using clinical trial data from two RCTs, finding that models combining PD-L1, TMB, and immune signatures outperform single biomarkers.

Journal of Translational Medicine · Feb 21, 2024Peer-reviewedCancer Biology

A Community Challenge for Pancancer Drug Mechanism of Action Inference from Perturbational Profile Data

E. F. Douglass, R. J. Allaway, B. Szalai, W. Wang, T. Tian, A. Fernandez-Torras, R. Realubit, C. Karan, S. Zheng, A. Pessia, Z. Tanoli, M. Jafari, F. Wan, S. Li, Y. Xiong, , A. Califano

The paper hosts a DREAM Challenge to evaluate computational models for predicting drug polypharmacology using perturbational profile data from 32 kinase inhibitors.

bioRxiv · Dec 21, 2020Cancer Biology